# US 2010/0167357 A1 · Obligate heterodimer meganucleases and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167357 A1
- Document ID: US20100167357A1
- Status: Published application
- Kind: A1
- Application number: 12/449,329
- Filed: 2008-01-31
- Published: 2010-07-01
- Earliest claimed: 2007-02-01
- Assignees: Cellectis
- Inventors: Emmanuel Fajardo Sanchez; Sylvestre Grizot; Mark Isalan; Luis Serrand Pubul; Francois Stricher
- Web page: https://patentgrep.com/patent/US20100167357A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An obligate heterodimer meganuclease consisting of a first and a second monomer, deriving from two different homodimeric LAGLIDADG (SEQ ID NO: 66) endonuclease monomers (parent monomers), and having at least one pair of mutations interesting corresponding residues of said parent monomers which make an intermolecular interaction between the two monomers of each parent homodimeric LAGLIDADG (SEQ ID NO: 66) endonuclease, a vector encoding said meganuclease, a cell, an animal or a plant modified by said vector and the use of said meganuclease and derived products for molecular biology, genome engineering and genome therapy.

## Claims

### Claim 1

An obligate heterodimer meganuclease consisting of a first and a second monomer, deriving from two different parent homodimeric LAGLIDADG (SEQ ID NO: 66) endonuclease monomers, and having at least one pair of mutations interesting corresponding residues of said parent monomers which make an intermolecular interaction between the two monomers of each parent homodimeric LAGLIDADG (SEQ ID NO: 66) endonuclease, wherein the first mutation of said pair(s) is in the first monomer and the second mutation of said pair(s) is in the second monomer and said pair(s) of mutations impairs the formation of functional homodimers from each monomer without preventing the formation of a functional heterodimer able to cleave a non-palindromic hybrid DNA target comprising one different half of the DNA target cleaved by each parent homodimeric endonuclease.

### Claim 2 (depends on 1)

The obligate heterodimer meganuclease according to claim 1, wherein the monomers have at least one of the following pairs of mutations, respectively for the first and the second monomer:
a) the substitution of the glutamic acid at position 8 by a basic amino acid and the substitution of the lysine at position 7 by an acidic amino acid,
b) the substitution of the glutamic acid at position 61 by a basic amino acid and the substitution of the lysine at position 96 by an acidic amino acid,
c) the substitution of the leucine at position 97 by an aromatic amino acid and the substitution of the phenylalanine at position 54 by a small amino acid, and
d) the substitution of the aspartic acid at position 137 by a basic amino acid and the substitution of the arginine at position 51 by an acidic amino acid, said positions being indicated by reference to the I-CreI amino acid sequence SEQ ID NO: 1,

### Claim 3 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein the monomer having the substitution of the glutamic acid at position 8 or 61 by a basic amino acid, as defined in a) or b), further comprises the substitution of at least one of the lysine residues at positions 7 and 96, by an arginine.

### Claim 4 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein the monomer having the substitution of the leucine 97 by an aromatic amino acid as defined in c), further comprises the substitution of the phenylalanine at position 54 by a tryptophane.

### Claim 5 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein the monomer having the substitution of the phenylalanine at position 54 by a small amino acid as defined in c), further comprises the substitution of the leucine at position 58 or lysine at position 57, by a methionine.

### Claim 6 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein said acidic amino acid is a glutamic acid.

### Claim 7 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein said basic amino acid is an arginine.

### Claim 8 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein said aromatic amino acid is a phenylalanine.

### Claim 9 (depends on 2)

The obligate heterodimer meganuclease according to claim 2, wherein said small amino acid is a glycine.

### Claim 10 (depends on 1)

The obligate heterodimer meganuclease according to claim 1, which consists of a first monomer having at least the mutation D137R and a second monomer having at least the mutation R51D.

### Claim 11 (depends on 1, 2)

The obligate heterodimer meganuclease according to claim 1, which comprises at least two pairs of mutations as defined in a), b), c) or d) of claim 2.

### Claim 12 (depends on 11)

The obligate heterodimer meganuclease according to claim 11, wherein one monomer comprises the substitution of the lysine residues at positions 7 and 96 by an acidic amino acid and the other monomer comprises the substitution of the glutamic acid residues at positions 8 and 61 by a basic amino acid.

### Claim 13 (depends on 2, 11)

The obligate heterodimer meganuclease according to claim 11, which comprises three pairs of mutations as defined in a), b) and c) of claim 2.

### Claim 14 (depends on 13)

The obligate heterodimer meganuclease according to claim 13, which consists of a first monomer having at least the mutations K7R, EBR, E61R, K96R and L97F or K7R, EBR, F54W, E61R, K96R and L97F and a second monomer having at least the mutations K7E, F54G, L58M and K96E or K7E, F54G, K57M and K96E.

### Claim 15 (depends on 1)

The obligate heterodimerimeganuclease according to claim 1, which consists of two I-CreI monomer variants, further comprising different mutations at positions 26 to 40 and 44 to 77 of I-CreI.

### Claim 16 (depends on 15)

The obligate heterodimer meganuclease of claim 15, which is able to cleave a non-palindromic hybrid DNA target from a genomic sequence of interest corresponding to one different half of the DNA target that is cleaved by each parent homodimeric endonuclease.

### Claim 17 (depends on 1)

A single-chain meganuclease comprising the first and the second monomer of the obligate heterodimer meganuclease as defined in claim 1, connected by a peptidic linker.

### Claim 18 (depends on 1)

A monomer of the obligate heterodimer meganuclease according to claim 1.

### Claim 19 (depends on 18)

A polynucleotide fragment encoding the monomer of claim 18.

### Claim 20 (depends on 19)

A recombinant vector comprising at least one polynucleotide fragment of claim 19.

### Claim 21 (depends on 1)

An expression vector comprising two polynucleotide fragments each encoding one of the two monomers of the obligate heterodimer meganuclease of claim 1, said fragment(s) being operatively linked to regulatory sequences allowing the production of the two monomers.

### Claim 22 (depends on 17)

An expression vector comprising a polynucleotide fragment encoding the single-chain meganuclease according to claim 17, said fragment being operatively linked to regulatory sequences allowing the production of said single-chain meganuclease.

### Claim 23 (depends on 21)

The vector of claim 21, which includes a targeting DNA construct comprising sequences sharing homologies with the region surrounding a non-palindromic hybrid DNA target sequence comprising one different half of the DNA target cleaved by each parent homodimeric endonuclease.

### Claim 24 (depends on 23)

The vector of claim 23, wherein said targeting DNA construct comprises: a) sequences sharing homologies with the region surrounding a non-palindromic hybrid DNA target sequence comprising one different half of the DNA target cleaved by each parent homodimeric endonuclease, and b) sequences to be introduced flanked by sequence as in a).

### Claim 25 (depends on 19)

A host cell comprising one or two polynucleotide fragments as defined in claim 19.

### Claim at position 26

26-31. (canceled)

### Claim 32 (depends on 1)

A method of genetic engineering comprising double-strand nucleic acid breaking in a site of interest located on a vector comprising an hybrid DNA target as defined in claim 1, by contacting said vector with an obligate heterodimer meganuclease according to claim 1, thereby inducing a homologous recombination with another vector presenting homology with the sequence surrounding the cleavage site of said obligate heterodimer meganuclease.

### Claim 33 (depends on 1)

A method of genome engineering comprising: 1) double-strand breaking a genomic locus comprising an hybrid DNA target as defined in claim 1, by contacting said DNA target with an obligate heterodimer-meganuclease according to claims 1; and 2) maintaining said broken genomic locus under conditions appropriate for homologous recombination with a targeting DNA construct comprising the sequence to be introduced in said locus, flanked by sequences sharing homologies with the targeted locus.

### Claim 34 (depends on 1)

A method of genome engineering comprising: 1) double-strand breaking a genomic locus comprising at least one hybrid DNA target as defined in claim 1, by contacting said target with an obligate heterodimer meganuclease according to claims 1; and 2) maintaining said broken genomic locus under conditions appropriate for homologous recombination with chromosomal DNA sharing homologies to regions surrounding the targeted locus.

### Claim 35 (depends on 1)

A composition comprising at least one obligate heterodimer meganuclease according to claim 1.

### Claim 36 (depends on 35)

The composition according to claim 35, further comprising a targeting DNA construct comprising the sequence which repairs the site of interest flanked by sequences sharing homologies with the targeted locus.

### Claim at position 32

37-40. (canceled)
